The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
Stocks are bouncing higher but could be trapped in a range longer term, until there's a resolution of the trade wars.Market Insiderread more
Powell will have the opportunity if not to walk back the "midcycle" assessment then to at least provide some further explanation about what it means.Economyread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
The Business Roundtable, led by Jamie Dimon, gives a new definition of the "purpose of a corporation."Marketsread more
Tilman Fertitta told CNBC on Monday that he is doing things in a "very conservative way" amid fears of a recession.Marketsread more
Saudi Aramco sent a request for proposal to several banks, people familiar with the matter told CNBC on Monday.Marketsread more
Twitter and Facebook have suspended numerous accounts that are believed to be tied to a state-backed information campaign originating from inside China.Technologyread more
Leaked documents from Google give fresh ammo to conservative lawmakers who have already accused Google and other tech companies of political bias.Technologyread more
J.P. Morgan estimates the average annual tariff cost per household will be $1,000 with the new round of Trump's tariffs.Marketsread more
Stasior left Apple earlier this year. Prior to his time in charge of Siri, he was a top executive at Amazon.Technologyread more
Pfizer's quarterly revenue missed analysts' estimates on Tuesday, hurt by lower-than-expected sales of blockbuster breast cancer drug Ibrance and arthritis drug Xeljanz.
Ibrance raked in sales of $933 million in the first quarter, up 37.4 percent from a year earlier, but missed analysts' estimates of $956.6 million, according to Thomson Reuters I/B/E/S.
The drug faces competition from Novartis' Kisqali and Lilly's recently approved Verzenio.
Xeljanz, which is approved to treat rheumatoid arthritis and psoriatic arthritis, posted sales of $326 million, well below $398.5 million expected by analysts.
Shares of the largest U.S. drugmaker fell 1.67 percent to $36 in premarket trading on Tuesday.
Pfizer, which has been exploring options for its consumer healthcare business, said it expected to make a decision in 2018.
The company hoped to bring in $20 billion through an auction for the business, which includes Centrum vitamins and Advil painkillers.
Pfizer's quarterly profit, however, topped Wall Street estimates on stronger-than-expected sales of pneumonia vaccine Prevnar. The company also reaffirmed its 2018 forecast.
Prevnar recorded sales of $1.38 billion, which was slightly better than what analysts were expecting.
Net profit rose to $3.56 billion, or 59 cents per share, in the latest quarter ended April 1 from $3.12 billion, or 51 cents per share, a year earlier.
Excluding items, the company earned 77 cents per share, topping estimates of 74 cents.
Total revenue rose 1 percent to $12.91 billion, while analysts were expecting $13.13 billion.